Elysium Therapeutics, Inc. Employee Directory
Biotechnology ResearchUnited States2-10 Employees
Elysium’s mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need: Technologies 1. O2P™ (Oral Overdose Protection) – Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose. 2. XpiRx™ (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses. 3. SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are too short-acting and weak against synthetic opioids, often requiring multiple doses. SOOPR lasts up to 24 hours and is more effective against synthetic opioids (e.g., fentanyl, nitazenes) than today’s standard-of-care Elysium has a highly attractive risk/reward profile: 1. High-probability of Success: In vitro and in vivo proof-of-concept data for its new chemical entities that are comprised of FDA-approved drugs 2. Capital Efficiency: Leveraging non-dilutive grant funding, ~$16M to-date 3. Platform Opportunity: Diversified portfolio of programs addressing the key underlying factors that are driving the opioid crisis and could yield multiple products within 3-5 years 4. Market: Multi-billion-dollar market potential, with weak direct pipeline competition 5. Intellectual Property: Strong protection, with issued patents in the US and internationally, including composition of matter
1-888-653-2347 
support@leadiq.com 
